AIM: The aim of this study was to explore the effects and mechanism of berbamine on imatinib-resistant BCR-ABL-positive human leukemia K562 (K562-r) cells in vitro and in vivo. METHODS: Cell viability was measured by MTT assay, and apoptotic morphology changes were detected by fluorescence microscopy. The apoptosis rate was measured by flow cytometric assay. mdr-1 mRNA levels were determined by RT-PCR. Bcl-2 family proteins, cytochrome c(cyt C), poly (ADP-ribose) polymerase (PARP), and P-glycoprotein were detected by Western blot. BALB/c nu/nu mice were injected with K562-r cells subcutaneously. Tumor-bearing mice were treated intravenously with berbamine. RESULTS: MTT tests revealed that berbamine significantly inhibited K562-r cell proliferation and increased the chemo-sensitivity of K562-r cells to imatinib. The apoptosis rate was significantly increased following treatment with 21.2 micromol/L berbamine; formation of typical apoptotic blebs was apparent, as observed by fluorescence microscopy. Expression levels of mdr-1 mRNA and P-gp protein were high in untreated K562-r cells and significantly down-regulated by berbamine treatment. Berbamine-treated K562-r cells also exhibited down-regulated expression of the anti-apoptotic proteins Bcl-2 and Bcl-x(L), up-regulated expression of the apoptotic proteins Bax and cytoplasmic cyt C, and stimulated proteolytic cleavage of PARP. In addition, berbamine also suppressed the growth of K562-r xenotransplanted tumors in vivo. CONCLUSION: Berbamine inhibited proliferation of K562-r cells both in vitro and in vivo. Berbamine-induced apoptosis in K562-r cells appeared to occur through a mechanism involving Bcl-2 family proteins, as well as mdr-1 mRNA and P-gp protein. Berbamine in combination with imatinib restored the chemo-sensitivity of K562-r cells to imatinib. Our findings suggest that berbamine may be useful in treating imatinib-resistant CML patients.
AIM: The aim of this study was to explore the effects and mechanism of berbamine on imatinib-resistant BCR-ABL-positive humanleukemia K562 (K562-r) cells in vitro and in vivo. METHODS: Cell viability was measured by MTT assay, and apoptotic morphology changes were detected by fluorescence microscopy. The apoptosis rate was measured by flow cytometric assay. mdr-1 mRNA levels were determined by RT-PCR. Bcl-2 family proteins, cytochrome c(cyt C), poly (ADP-ribose) polymerase (PARP), and P-glycoprotein were detected by Western blot. BALB/c nu/nu mice were injected with K562-r cells subcutaneously. Tumor-bearing mice were treated intravenously with berbamine. RESULTS:MTT tests revealed that berbamine significantly inhibited K562-r cell proliferation and increased the chemo-sensitivity of K562-r cells to imatinib. The apoptosis rate was significantly increased following treatment with 21.2 micromol/L berbamine; formation of typical apoptotic blebs was apparent, as observed by fluorescence microscopy. Expression levels of mdr-1 mRNA and P-gp protein were high in untreated K562-r cells and significantly down-regulated by berbamine treatment. Berbamine-treated K562-r cells also exhibited down-regulated expression of the anti-apoptotic proteins Bcl-2 and Bcl-x(L), up-regulated expression of the apoptotic proteins Bax and cytoplasmic cyt C, and stimulated proteolytic cleavage of PARP. In addition, berbamine also suppressed the growth of K562-r xenotransplanted tumors in vivo. CONCLUSION:Berbamine inhibited proliferation of K562-r cells both in vitro and in vivo. Berbamine-induced apoptosis in K562-r cells appeared to occur through a mechanism involving Bcl-2 family proteins, as well as mdr-1 mRNA and P-gp protein. Berbamine in combination with imatinib restored the chemo-sensitivity of K562-r cells to imatinib. Our findings suggest that berbamine may be useful in treating imatinib-resistant CMLpatients.
Authors: M Mancini; G Brusa; M Benvenuti; L Mazzacurati; F Campanini; E Barbieri; S Cammelli; N Calonghi; G Martinelli; M Baccarani; M A Santucci Journal: Leukemia Date: 2004-02 Impact factor: 11.528
Authors: Susan Branford; Zbigniew Rudzki; Sonya Walsh; Andrew Grigg; Chris Arthur; Kerry Taylor; Richard Herrmann; Kevin P Lynch; Timothy P Hughes Journal: Blood Date: 2002-05-01 Impact factor: 22.113
Authors: Nikolas von Bubnoff; Darren R Veach; W Todd Miller; Wanqing Li; Jana Sänger; Christian Peschel; William G Bornmann; Bayard Clarkson; Justus Duyster Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701
Authors: T Illmer; M Schaich; U Platzbecker; J Freiberg-Richter; U Oelschlägel; M von Bonin; S Pursche; T Bergemann; G Ehninger; E Schleyer Journal: Leukemia Date: 2004-03 Impact factor: 11.528
Authors: Y Zhao; J J Lv; J Chen; X B Jin; M W Wang; Z H Su; L Y Wang; H Y Zhang Journal: Prostate Cancer Prostatic Dis Date: 2016-07-19 Impact factor: 5.554
Authors: Lukmanee Tradtrantip; Hua Zhang; Marc O Anderson; Samira Saadoun; Puay-Wah Phuan; Marios C Papadopoulos; Jeffrey L Bennett; A S Verkman Journal: FASEB J Date: 2012-02-08 Impact factor: 5.191
Authors: Sangkil Nam; Jun Xie; Angela Perkins; Yuelong Ma; Fan Yang; Jun Wu; Yan Wang; Rong-Zhen Xu; Wendong Huang; David A Horne; Richard Jove Journal: Mol Oncol Date: 2012-06-02 Impact factor: 6.603
Authors: Kodappully S Siveen; Kirti S Prabhu; Iman W Achkar; Shilpa Kuttikrishnan; Sunitha Shyam; Abdul Q Khan; Maysaloun Merhi; Said Dermime; Shahab Uddin Journal: Mol Cancer Date: 2018-02-19 Impact factor: 27.401